University of Central Florida Research Foundation Inc

Baylor College of Medicine

Temple University

Saleh Naser

Solodnikov Sergey Yurjevich

D Howard Miles

Krasnykh Olga Petrovna

Elena A Goun

Suslonov Vladimir Michailovich

Charalambos Kaittanis

J Manuel Perez

David Y Graham

John Todd Kuenstner

Ira Shafran

Fouad A El-Zaatari

Irene Grant

Antonio Foddai

Raghava Potula

Tim Bull

The present invention provides a semi-quantitative phage-based assay for Mycobacterial infection, in which the phage assay plaque count correlates to the number of viable Mycobacterial organisms in the subject sample, and methods of use thereof for diagnosing, treating or monitoring Mycobacterial infection.

Method and system for detection of mycobacteria in human samples

Disclosed herein are methods and materials for facilitating the detection of nucleic acid analytes of interest. Specifically exemplified herein are methods for detecting mycobacterial microorganisms, namelyspp.. Also disclosed is new hybridizing magnetic relaxation nanosensor (hMRS) particularly adapted to detect a target nucleic acid analyte of interest.

Microbe detection via hybridizing magnetic relaxation nanosensors

A method and kit for detection ofSubspecies Paratuberculosis (MAP) in blood and blood derivative samples from humans by culture and PCR. Technology can screen for MAP in blood samples from millions of patients having inflammatory and non-inflammatory bowel diseases, and the results are used to identify those patients with MAP for treatment by antibiotics. The method and kit can monitor and evaluate the outcome of therapy.

[object Object]

A novel class of methyl esters of substituted 4-oxo-2-butenoic acids and their derivatives are disclosed along with the surprising use property of these compounds as a bacteriostatic agents for humans or non-humans against mycobacteria. These compounds include: 4-(4-Ethoxy-phenyl)-2-(N&prime;-fluoren-9-ylidene-hydrazino)-4-oxo-but-2-enoic acid methyl ester; 4-(4-Ethoxy-phenyl)-2-(N&prime;-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester; 2-(4-Bromo-phenylamino)-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl ester; A pharmaceutical composition is disclosed as well as the method of treating human and non-humans infected with and related mycobacteria.

Methyl esters of substituted 4-oxo-2-butenoic acid for treatment of tuberculosis

Compounds belonging to novel classes of 2-oxo-1,4-benzoxazine heterocyclic compounds and their close derivatives, are disclosed along with the surprising use property of these compounds as bacteriostatic agents for humans and non-humans against mycobacteria. These species include: 4-benzoyl-3-benzoyloxy-2-(2-oxo-2H-1,4-benzoxazin-3-yl)pyrido&lsqb;2,1-c&rsqb;&lsqb;1,4&rsqb;benzoxazin-1,5-dione; and, 2,4,6-trimethylphenyl 2-(3,4-dihydro-2-oxo-2H-1,4-benzoxazin-3-ylidene)-3-p-methoxyphenyl-3-oxo-propanoate.

2-oxo-1, 4-benzoxazine compounds for treatment of tuberculosis

Recombinant clone pMptb #48 expressing a 36k M. paratuberculosis antigen is provided that provides a more sensitive and discriminating test than those in which crude antigens have been used. A mycobacterial genus-specific DNA probe corresponding to a 1.4 kb BamH1-DNA insert in pMptb #48 is also provided. The 1.4 kb insert includes the entire DNA coding sequence for an M. paratuberculosis 36k protein. There is also provided methods for serologically testing specimens which include the use of recombinant clone pMptb #48 and/or the p36k protein and/or fragments of the p36k protein. Also provided are methods for identifying mycobacterial infections using a probe corresponding to the 1.4 kb DNA sequence shown in FIG. 4, the coding portion of the 1.4 kb DNA sequence, or fragments thereof.

Mycobacterial genus-specific DNA probe and its expressed product

Growing community of inventors

Orlando, FL, United States of America

Saleh Naser